Former Vice President and Global Head of Quantitative Clinical Pharmacology at AstraZeneca Joins NDA Partners

Share Article

NDA Partners Chairman Carl Peck, MD, announced today that Donald Stanski, MD, a senior pharmaceutical industry executive and expert in clinical pharmacology and pharmacometrics has joined the firm as an Expert Consultant. Dr. Stanski is widely recognized for his expertise in applying systems pharmacology modeling and simulation and advanced statistical analytics with drug and disease models.

News Image
Dr. Stanski’s expertise in clinical pharmacology and pharmacometrics, in addition to his leadership in applications of systems pharmacology modeling and simulation for drug and disease strategic data analytics, will bring high value to our drug development clients.

NDA Partners Chairman Carl Peck, MD, announced today that Donald Stanski, MD, a senior pharmaceutical industry executive with expertise in clinical pharmacology and pharmacometrics and a widely recognized expert in systems pharmacology modeling and simulation for drug and disease strategic data analytics, has joined the firm as an Expert Consultant.

Dr. Stanski has served in senior executive roles as Vice President and Global Head, Quantitative Clinical Pharmacology at AstraZeneca Pharmaceuticals and Vice President and Global Head, Modeling and Simulation at Novartis Pharma AG. He was formerly a Scientific Advisor to the FDA Deputy Commissioner, where he introduced new quantitative methods into the regulatory review process for drugs and medical devices. In addition to his industry career, he served as Professor and Chairman of the Department of Anesthesiology at Stanford University’s School of Medicine. He currently serves as Professor Emeritus at Stanford.

“We are very pleased to welcome Dr. Stanski to NDA Partners,” said Dr. Peck. “Dr. Stanski’s expertise in clinical pharmacology and pharmacometrics, in addition to his leadership in applications of systems pharmacology modeling and simulation for drug and disease strategic data analytics, will bring high value to our drug development clients.”

Dr. Stanski received his medical degree from the University of Calgary in Calgary, Alberta, Canada, where he also completed his pharmacy pre-medicine courses. Dr. Stanski has authored numerous publications and has served on several editorial boards including Anesthesiology, Clinical Pharmacology and Therapeutics, and Journal of Pharmacokinetics and Biopharmaceutics.

About NDA Partners
NDA Partners is a life sciences management consulting and contract development organization (CDO) focused on providing product development and regulatory services to the pharmaceutical, biotechnology, and medical device industries worldwide. The highly experienced Principals and Expert Consultants in NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; the former Chief Executive Officer and Chief Science Officer at the United States Pharmacopeial Convention (USP); an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and contract management of client product development programs.

Contact
Earle Martin, Chief Executive Officer
Office: 540-738-2550
MartinEarle@ndapartners.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Earle Martin
Visit website